Impact Biomedical Inc（IBO）財務資料IBOImpact Biomedical Inc

Evaluating the bottom line, Impact Biomedical Inc maintains a gross margin of -9400.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23400.00%, while the net margin is 28425.00%. These profitability ratios, combined with a Return on Equity (ROE) of 433.42%, provide a clear picture of how effectively IBO converts its operational activities into shareholder value.

In the context of the broader market, IBO competes directly with industry leaders such as LASE and ACFN. With a market capitalization of $35.42M, it holds a significant position in the sector. When comparing efficiency, IBO's gross margin of -9400.00% stands against LASE's 8.44% and ACFN's 80.55%. Such benchmarking helps identify whether Impact Biomedical Inc is trading at a premium or discount relative to its financial performance.

Impact Biomedical has shown mixed financial performance, with total revenue of $18,000 in Q3 2025 and a net income loss of -$1,470,000 in the same quarter. The gross margin has fluctuated significantly, with a recent gross margin of 100% in Q1 2026, but it was -4,171.43% in Q2 2025, indicating volatility in profitability.